treatment-resistant depression

Atai Life Sciences (NASDAQ:ATAI) announced promising preliminary results on Tuesday for its DMT-based depression therapy, VLS-01. As BioSpace reported, these findings from a Phase Ib study position Atai to move forward with a Phase II trial later this year, targeting patients with treatment-...

Pharma giant Johnson & Johnson (NYSE:JNJ) announced Monday it had asked the Food and Drug Administration (FDA) to approve its nasal spray as a monotherapy for treatment-resistant depression (TRD) in adults. The New Jersey-based company's Spravato, contains esketamine as an active ingredient,...

Private psychedelics medicine company Beckley Psytech Ltd announced this week that the first patient has been dosed in the second part of its two-part Phase IIa study evaluating BPL-003 in patients with treatment-resistant depression (TRD). BPL-003 is its proprietary...

Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a Phase 2a study of Beckley's novel formulation of 5-MeO-DMT in Treatment Resistant Depression (TRD.)  See: Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics...

Compass Pathways (NASDAQ:CMPS), one of the key players in the psychedelics biotech space, reported its financial results for the fourth quarter of 2023. Numbers: Cash and cash equivalents were $220.2 million by December 31, 2023, up over 50% as compared to the amount held by December 31, 2022 ($...

The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS) for Treatment-Resistant Depression and Awakn Life Sciences (OTCMKTS: AWKNF) for Severe Alcohol Use Disorder (SAUD). Details On Trials Compass...

Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) has completed its Phase 1 study evaluating proprietary oral transmucosal film (OTF) DMT formulation VLS-01 in 74 healthy participants. A DMT formulation, VLS-01 works as a partial agonist of the 5-HT 1A/2A/2C receptors, with an...

COMPASS Pathways plc (NASDAQ: CMPS) shared the results from research on the potential of its novel AI technologies to support its proprietary COMP360 psilocybin treatment for Treatment-Resistant Depression (TRD.) COMPASS is oner of the biggest players in the psychedelics biotech...

GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharma company developing novel mebufotenin (5-MeO-DMT) therapies for Treatment-Resistant Depression (TRD) and one of the highest trading psychedelics stocks listed in Nasdaq, shared its financial results and business updates for its second...

COMPASS Pathways (NASDAQ: CMPS) shared results from an open-label Phase 2 trial assessing its synthetic psilocybin COMP360 alongside SSRIs for Treatment-Resistant Depression (TRD.) Published in the journal Nature of Neuropsychopharmacology, the findings show a positive correlation, both...

Mental health psychedelics biotech company COMPASS Pathways (NASDAQ: CMPS) received funding for its COMP360 Phase 3 program in Treatment-Resistant Depression (TRD).  The company entered into a term loan agreement with Hercules Capital Inc. (NYSE: HTGC) for up to $50 million, filed under the...

Numinus Wellness Inc.’s (OTCMKTS: NUMIF) wholly-owned contract research organization Cedar Clinical Research has commenced a new study on COMPASS Pathways’ (NASDAQ: CMPS) psilocybin therapy for Treatment-Resistant Depression (TRD).  See also: Numinus CEO Outlines MDMA Assisted...

GH Research PLC (NASDAQ: GHRS), a Dublin-based clinical-stage biotech company reported financial results for the first quarter ended March 31, 2023. The company is developing a proprietary 5-MeO-DMT formulation primarily targeting Treatment-Resistant Depression (TRD). Numbers show: Total...

Clinical-stage private biotech company Beckley Psytech Ltd announced that the first patient has been dosed in their Phase IIa study of BPL-003, a synthetic formulation of the psychedelic compound 5-MeO-DMT, for Treatment-Resistant Depression (TRD). Dr. Rob Conley, chief scientific officer at...

After atai Life Sciences (NASDAQ: ATAI) shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psychedelics biotech’s stocks plummeted. The closing stock price on Jan. 11 was $1.72, more than 90% below its IPO price from...